PDUFA Commitment Letter Formalizes REMS Standardization Schedule
This article was originally published in The Pink Sheet Daily
Among other timetables set as part of the broad deal with industry, FDA will host meetings and issue guidances to assess and minimize the burden of REMS on the practitioners and patients.
You may also be interested in...
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.
FDA Simplifies The Process For REMS Changes
Some typographical changes can be submitted and noted later, according to new draft guidance. Major changes still require pre-approval.
FDA Quietly Consults Patients To Understand Vimizim's Six-Minute Walk Significance
Meeting with Morquio A patient and caregivers appears to have helped to assuage FDA concerns about clinical relevance of the Vimizim trial’s primary endpoint – and illustrates FDA’s openness to patient input even during specific reviews of new product applications.